Rhonda M. Chicko - 07 Aug 2025 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)

Reporting relationship: Chief Financial Officer
Issuer ticker: CYCN
Reported as of: 07 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Aug 2025, 16:05:06 UTC
Prior SEC filing: 11 Mar 2024
Next SEC filing: 18 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Rhonda Chicko

Key filing fact

Rhonda M. Chicko filed Form 4 for Cyclerion Therapeutics, Inc. (CYCN) on 11 Aug 2025.

Key facts

This page summarizes Rhonda M. Chicko's Form 4 filing for Cyclerion Therapeutics, Inc. (CYCN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Aug 2025, 16:05.

Change

Previous filing in this sequence was filed on 11 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001740376 Primary reporting owner

CHICKO RHONDA M.

Relationship: Chief Financial Officer
Address: C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE
Signature: /s/ Rhonda Chicko
Signature date: 11 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYCN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 07 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $2.36
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person was granted an option to purchase up to 25,000 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan. These 25,000 shares vest as follows: (i) 8,750 shares are immediately exercisable, and (ii) the remaining 16,250 shares vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remains as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.